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Abstract: Single-walled carbon nanotubes (SWNTs) have been identified as an efficient drug 
carrier. Here a controlled drug-delivery system based on SWNTs coated with doxorubicin 
(DOX) through hydrazone bonds was developed, because the hydrazone bond is more   sensitive 
to tumor microenvironments than other covalent linkers. The SWNTs were firstly stabilized with 
  polyethylene glycol (H2N-PEG-NH2). Hydrazinobenzoic acid (HBA) was then covalently attached 
on SWNTs via carbodiimide-activated coupling reaction to form hydrazine-modified SWNTs. 
The anticancer drug DOX was conjugated to the HBA segments of SWNT using hydrazine as 
the linker. The resulting hydrazone bonds formed between the DOX molecules and the HBA 
segments of SWNTs are acid cleavable, thereby providing a strong pH-responsive drug release, 
which may facilitate effective DOX release near the acidic tumor microenvironment and thus 
reduce its overall systemic toxicity. The DOX-loaded SWNTs were efficiently taken up by HepG2 
tumor cells, and DOX was released intracellularly, as revealed by MTT assay and confocal 
microscope observations. Compared with SWNT-DOX conjugate formed by supramolecular 
interaction, the SWNT-HBA-DOX featured high weight loading and prolonged release of DOX, 
and thus improved its cytotoxicity against cancer cells. This study suggests that while SWNTs 
have great potential as a drug carrier, the efficient formulation strategy requires further study.
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Introduction
Although most of the existing anticancer drugs are very potent small molecules, 
their efficacy is constrained not only by their side effects but also as a result of drug 
resistance and limited cellular entry. Thus it is important to develop efficient delivery 
systems to enhance cellular uptake of existing drugs. Carbon nanotubes (CNTs) have 
received considerable attention in biomedical applications due to their unique optical, 
electronic, chemical, and physiological properties.1,2 They have been shown to deliver 
various biomolecules including protein,3 DNA, and RNA4–6 into cells by endocytosis.7 
Functionalized water-soluble CNTs (f-CNTs) were suggested to be compatible and 
nontoxic at the cellular level.8,9 Furthermore, the one-dimensional structure of CNTs 
may have advantages over existing delivery vectors, including an enhanced capacity to 
penetrate cellular membranes and high surface area to provide sites to carry multiple 
moieties at high density.10–12 These properties made f-CNTs a promising candidate 
for drug delivery system.
There have been a number of promising reports in recent years on the   conjugation 
of f-CNTs with drug molecules for delivery applications. Doxorubicin (DOX) has been 
noncovalently bound to CNTs by means of π–π stacking interactions, hydrophobic 
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interactions,13–15 and electrostatic interaction.16 Since the 
noncovalent interaction is not as robust as covalent linkage, 
the early release of the drug before reaching the pharma-
cologic tissues should be inevitable. Small drug molecules 
have been covalently conjugated to f-CNTs through amide 
bonds,12 disulfide bonds,17 ester bonds,18,19 and carbam-
ate bonds20 for in-vitro and in-vivo delivery. To improve 
the cellular uptake of tumor cells, drug molecules were 
linked to the same nanotubes together with tumor-targeting 
molecules that could specifically recognize cancer-specific 
receptors on the cell surface and induce receptor-mediated 
endocytosis. Compared with the tumor-associated receptors, 
tumor microenvironment indicators including acidosis21 
and hypoxia22 are universal phenomena of solid tumors, 
regardless of the tumor types or its developmental stages. 
The acidic extracellular environment is perhaps the most 
pervasive of tumor microenvironments. Therefore, a drug-
delivery system that is responsive in the physiologically 
acidic pH range (4.5–6.9) is promising for the drug release 
inside tumor cells.23
Despite excellent progress in using single-walled carbon 
nanotubes (SWNTs) as drug-delivery vehicles, more research 
is needed to further optimize their application to selective 
accumulation in diseased tissues and to release their toxic 
payload in a controlled manner. Hydrazones, formed by 
condensation of the C-13 ketone of DOX with a hydrazine, 
have been used for attaching drugs to polymers24–26 and 
nanoparticles.27,28 However, there is no report on the cova-
lent immobilization of anticancer drug onto the surfaces of 
functionalized SWNTs through hydrazone linkage. Presented 
herein is the preparation of the SWNT-hydrazone-DOX 
delivery system, in which the antitumor agent DOX was 
covalently linked to SWNTs through biocleavable hydra-
zone linkage. The strategies presented in this paper may 
lead to improved tumor-targeting efficacy via the enhanced 
permeability and retention effect and pH-controlled DOX 
release, thereby improving the efficacy of cancer therapy. 
This study provides the fundamental characteristics of a 
pH-responsive SWNT-based system for improved intracel-
lular drug delivery.
Materials and methods
Chemicals and materials
SWNTs  were  purchased  from  Nanostructured  and 
  Amorphous Materials Inc (Houston, TX). DOX   hydrochloride 
(DOX⋅HCl), N-hydroxy succinimide (NHS), (N-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(EDC), 3-(4,5-  dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), and polyoxyethylene bis(amine) (NH2-PEG-
NH2) (with a molecular weight [MW] of 3350) were   purchased 
from Sigma-Aldrich (St Louis, MO) at reagent grade and used 
without further purification. 4-  Hydrazinobenzoic acid (HBA) 
was purchased from International Laboratory Ltd (San 
Bruno, CA). Microcon centrifugal filter device (YM-100, 
regenerated cellulose 10,000 MW cutoff [MWCO]) was 
purchased from Millipore (Bellerica, MA). Spectra/Por® 
dialysis membrane (MW 12,000–14,000) was purchased 
from Spectralabs (Rancho Dominguez, CA).
Characterization
The morphologies and structures of SWNT, SWNT-PEG-
NH2, and SWNT-HBA-DOX conjugates were characterized 
by a transmission electron microscopy (Philips Tecnai 20, 
FEI Co, Eindhoven, The Netherlands) with an accelerating 
voltage of 200 kV . Samples were prepared by drying droplets 
of a sample in ethanol dispersed onto carbon-coated copper 
grids. Ultraviolet-visible (UV-Vis) spectra were recorded 
using a UV-Vis-near-infrared spectrophotometer (UV-3150; 
Shimadzu Co, Kyoto, Japan). Fluorescence spectra were 
measured on a fluorescence spectrometer (F-7000; Hitachi, 
Tokyo, Japan).
Preparation of DOX-conjugated SWNTs 
through hydrazone linkage
The PEGylated SWNTs (SWNT-PEG-NH2) were synthe-
sized according to a previous report.29 The DOX attached to 
SWNTs through hydrazone bond was then prepared accord-
ing to the following steps. The SWNT-PEG-NH2 (5 mL) was 
suspended with HBA (30 mg) in a pH 7.4 phosphate buffered 
saline (PBS) solution (5 mL), EDC ⋅ HCl (48 mg), and NHS 
(20 mg) was then added. The mixture was allowed to react 
at room temperature for 24 hours, after which the conjugate 
was dialyzed against H2O to remove unreacted reagent 
to obtain SWNT-HBA complex. Finally, the solution was 
freeze-dried to obtain the hydrazine modified SWNTs as a 
fine powder. DOX can be bound to SWNTs by the reaction of 
SWNT-HBA with DOX ⋅ HCl in dimethyl sulfoxide (DMSO) 
in the dark according to the method previously described in 
the   literature.30 Five milligrams of freeze-dried hydrazine-
modified SWNTs was dissolved in 5 mL anhydrous DMSO, 
and excess amount of DOX ⋅ HCl (10 mg) was added. The 
mixture solution was stirred at room temperature in the dark 
for 24 hours. After the reaction, the solution was transferred 
into a dialysis tubing (MWCO of 12,000 Da) and dialyzed 
against Milli-Q® (Millipore) water for 3 days to remove the 
excess amount of unbounded DOX molecules and DMSO. 
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The amount of DOX loaded onto SWNTs was measured by 
the absorbance peak at 490 nm (characteristic of DOX, after 
subtracting the absorbance of SWNTs at that wavelength) 
based on a standard curve of DOX. The DOX weight load-
ing was defined as the weight ratio of the attached DOX to 
the SWNTs.
Evaluation of pH sensitivity
The rate of DOX released from SWNTs was measured as a 
function of time during incubation in 0.1 M PBS at pH 7.4 and 
pH 5.5. Triplicate samples of 0.4 mL of SWNT-HBA-DOX 
and SWNT-DOX (the detail of preparation of SWNT-DOX 
is described in Supplementary Figure 1) were suspended 
in 10 mL PBS in a microcentrifuge tube. The samples 
were then incubated at room temperature. The nanotubes 
were centrifuged and 4 mL of supernatant was periodically 
removed and the same volume of fresh PBS solution was 
added afterward. The amount of released DOX was analyzed 
by UV-vis   spectrophotometry at 490 nm.
Cell culture and intracellular DOX 
trafficking
Human hepatocellular carcinoma cells (HepG2, American 
Type Culture Collection [ATCC] No: HB8065) and human 
cervical adenocarcinoma cells (HeLa, ATCC No: CCL2) 
were purchased from ATCC (Manassas, VA) and cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) (Cat # 
12800-017; Invitrogen, Carlsbad, CA) with 10% fetal bovine 
serum (Cat # 10082-147; Invitrogen) and 100 U/mL   penicillin 
and 100 µg/mL streptomycin (Cat # 15070-0;   Invitrogen). The 
cells were maintained at 37°C in a   humidified atmosphere 
containing 5% CO2 and regularly passaged by trypsinization 
with 0.05% trypsin in PBS (pH 7.4).
The cellular uptake and distribution of DOX from the 
SWNT-HBA-DOX conjugates were examined under a Leica 
TCS SPE confocal microscope (Leica Microsystems GmbH, 
Wetzlar, Germany). Both bright view differential interference 
contrast images and confocal images were obtained with a 
40× (oil immersion, numerical aperture 1.25) objective. For 
confocal microscope observation, HepG2 cells were grown 
on coverslips in a 6-well plate 1 day before the experiment. 
Cells were treated with SWNT-DOX and SWNT-HBA-DOX 
(DOX concentration 15 µg/mL) for 2 hours. The cells were 
then thoroughly washed with PBS and incubated in fresh 
culture medium. The intracellular distribution of DOX was 
then examined under the confocal microscope. The fluores-
cence intensity was measured and analyzed with MetaMorph 
(Universal Imaging, Downingtown, PA).
Cell viability
The cytotoxicity of SWNT-DOX and SWNT-HBA-DOX 
against HepG2 cells was assessed using the MTT assay. 
HepG2 cells were seeded into a 96-well microtiter plate at 
a density of 1 × 104 cells/well in 150 µL DMEM medium 
24 hours before treatment. The cells were then exposed to 
a series of concentrations of SWNTs, SWNT-DOX, and 
SWNT-HBA-DOX conjugates for 24 hours. The dose of 
SWNT-DOX and SWNT-HBA-DOX was set according to 
the contained DOX dose in the conjugates within a range of 
0.25–10.0 µg/mL (0.43–17.2 µM) of DOX. After   incubation 
for 24 hours, the cells were washed three times with warm 
PBS and incubated for another 4 hours containing 0.5 mg/mL 
of MTT solution. After discarding the culture medium, 
100 µL of 50% DMSO: 50% ethanol was added to dis-
solve the formazan crystals, and the resulting solution was 
  measured for absorbance at 570 nm using a microplate reader. 
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Figure 1 Schematic illustration of the SWNT-HBA-DOX. The DOX (blue color) was attached to SWNT through hydrazone linkage (red color) and supramolecular 
interaction, respectively.
Abbreviations:  DMSO,  dimethyl  sulfoxide;  DOX,  doxorubicin;  EDC,  (N-(3-dimethylaminopropyl)-3-ethylcarbodiimide  hydrochloride;  HBA,  hydrazinobenzoic  acid; 
NHS, N-hydroxy succinimide; SWNT, single-walled carbon nanotube.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2891
Carbon nanotube-doxorubicin complexesInternational Journal of Nanomedicine 2011:6
Cells incubated with blank cell culture medium were used 
as reference for 100% viability. The mean percentage of 
cell survival relative to that of untreated cells was estimated 
from data from five replicates. The results were expressed as 
viability (%) relative to a control without any treatment.
To further evaluate the drug release efficiency from 
SWNTs, HepG2 cells were incubated with a specific concen-
tration (DOX concentration: 17.2 µM) of SWNT-HBA-DOX 
and SWNT-DOX in culture medium at 37°C for 2 hours. The 
medium was then replaced with fresh medium and incubated 
again for 24, 48, and 72 hours. The cells were washed three 
times with warm PBS before further analysis by MTT.
Statistical analysis
All data are presented as mean ± standard deviation from 
3–6 experiments. Significant differences between mean 
values were determined using two-way analysis of   variance 
(ANOVA) and Tukey’s post-hoc test. The level of   statistical 
significance in all cases was P , 0.05.   Percentage data was 
log transformed before analysis. ANOVA was performed 
using SPSS (v 19.0; IBM SPSS, Chicago, IL) software.
Results and discussion
Synthesis and characterization  
of SWNT-HBA-DOX nanoconjugates
DOX is one of the widely used chemotherapeutic agents in the 
treatment of cancers. The exact mechanism of its antitumor activ-
ity still remains unclear. It is known, however, that DOX interca-
lates into DNA, which results in the blocking of topoisomerase 
II activity, preventing DNA replication and cell division.31–33 For 
DOX-loaded nanoconjugates, the efficacy depends not only on 
cellular uptake but also on their release efficiency inside the 
cancer cells. The controlled release is mainly achieved through 
cleavable linkers. Hence, discovery of a reliable method to load 
and release DOX from SWNTs is attractive.
Hydrazone bond was employed in this work to connect 
DOX, as it is more sensitive to tumor microenvironments 
than other covalent linkers. The reaction scheme for the syn-
thesis of SWNT-HBA-DOX conjugate is shown in Figure 1. 
Functionalization of SWNTs with H2N-PEG-NH2 (PEG) 
is based on the authors’ previously described method.29 To 
conjugate DOX onto SWNT-PEG-NH2 through hydrazone 
bond, the amine groups on SWNT-PEG-NH2 were firstly 
coupled with the carboxylic acid terminal groups of HBA to 
form hydrazine-modified SWNTs using EDC and NHS as the 
catalysts. Thereafter, DOX was conjugated to the SWNTs by 
forming acid-sensitive hydrazone bonds (SWNT-HBA-DOX) 
between the hydrazine moiety attached to SWNTs and 
ketonic groups of DOX. For comparison, DOX was also 
attached to SWNTs through noncovalent interaction (SWNT-
DOX) by simply mixing the SWNT-PEG-NH2 with DOX in 
aqueous solution (Supplementary Figure 1). Note that free 
DOX in the SWNT solution was removed thoroughly by 
repeated filtrations with a 10 kD molecular cutoff to obtain 
SWNT-HBA-DOX and SWNT-DOX complexes.
To investigate the immobilization of HBA on SWNTs, the 
infrared (IR) spectroscopy was applied for the characterization 
of SWNT-PEG-HBA, HBA, and SWNT-PEG-NH2. The 
measurement results of the prepared samples are presented 
in Figure 2A, with the IR region from 4000 to 500 cm−1. The 
Fourier transform IR (FTIR) spectrum for HBA displays bands 
at 1645 and 3263 cm−1, which are attributed to the C=O and 
NH2 groups, and various bands between 3000 and 2700 cm−1, 
which represent the intermolecular hydrogen bond between 
the carbonyl and the amino groups.34 The SWNT-PEG-NH2 
sample shows peaks at 3420, 1730, and 1102 cm−1. The 
bands at 1730 cm−1 are attributed to the C=O bonds from 
carboxylic acid groups, and the bands at 3420 and 1102 cm−1 
represent the stretching frequency of -O-H groups and C-O 
stretching frequencies. It also shows an unobvious shoulder 
at 1636 cm−1 (inset in Figure 2A) which is attributed to the 
carbonyl group. The weak signal is due to the low amount of 
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Figure 2 (A) Infrared spectra of SWNT-PEG-HBA, HBA, and SWNT-PEG-NH2 
composites. Inset: enlargement of of infrared spectrum of SWNT-PEG-NH2. TEM 
images of (B) raw SWNT and (C) SWNT-PEG-NH2.
Abbreviations: HBA, hydrazinobenzoic acid; PEG, polyethylene glycol; SWNT, 
single-walled carbon nanotube; TEM, transmission electron microscopy.
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carbonyl group on SWNT-PEG-NH2 and the detection limit 
of the FTIR instrument. According to one report,35 the N-H 
peaks should appear at ∼3409 cm−1. However, in this present 
case, it was difficult to discern the -O-H (3420 cm−1) and 
N-H (3409 cm−1) peaks for SWNT-PEG-NH2 sample because 
of the overlay of these two peaks and the detection limit of the 
instrument. After the reaction of HBA with SWNT-PEG-NH2, 
the peaks at 1666 cm−1 in spectrum of SWNT-HBA can be 
assigned to amide bond, suggesting chemical complexation 
of carboxylic acid groups on HBA with amine groups on 
SWNTs. Additionally, the band at 2360 cm−1 is the typical IR 
bands of CO2 likely adsorbed on SWNTs. The morphology 
of SWNTs was also investigated by transmission electron 
microscopy (TEM). Figure 2B and C show the TEM images 
of raw SWNTs and SWNT-PEG-NH2. The SWNT-PEG-NH2 
appeared to be rough and without impurity compared with raw 
SWNTs, which indicate that metal particles and amorphous 
carbon have been removed. The morphologies of SWNT-
HBA-DOX and SWNT-DOX were also analyzed by TEM. 
No detectable change was found in comparison with that of 
SWNT-PEG-NH2.
DOX loading on the modified SWNTs
All the modified SWNTs were quite soluble in aqueous 
medium, which attribute to the high density of the hydrophilic 
glycol chains on the surface of SWNTs. The SWNT-HBA-
DOX and SWNT-DOX dispersed in H2O both displayed a 
UV-Vis absorption peak at 490 nm, characteristic of DOX 
(Figure 3A). Consequently, the amount of DOX loaded onto 
SWNTs was measured by the absorbance peak at 490 nm 
based on a standard curve of DOX in SWNTs solution. 
The DOX weight loading on SWNT-HBA was obtained to 
be 220%, which was higher than that on SWNTs of 160% 
(Figure 3B). Previously, it has been shown that DOX can 
be adsorbed onto the sidewalls of SWNTs via π–π stacking 
interactions,11 by simply mixing the SWNTs with DOX. 
In contrast, DOX was conjugated on HBA-coated SWNTs 
via not only hydrazone bond but also via π–π stacking 
interactions, thereby allowing the higher loading of DOX 
on SWNT-HBA-DOX than SWNT-DOX conjugate. The 
result indicated that hydrazone bond as well as π–π stacking 
interactions played an important role with respect to DOX 
loading capacity on SWNTs.
DOX release from modified SWNTs
The drug-release profiles of SWNT-HBA-DOX and SWNT-
DOX were investigated under simulated physiological 
conditions (PBS, pH 7.4) and in an acidic environment 
(PBS, pH 5.5) at room temperature, which assess the release 
efficacy of using SWNTs as the drug carrier. As shown 
in Figure 4A and B, the rate and amount of DOX were 
dependent on the pH of the medium. It showed that the 
DOX on   modified SWNTs supports was stable in PBS buf-
fer at pH 7.4. In slightly acidic conditions, such as pH 5.5, 
  corresponding to lysosomal pH, an appreciable release DOX 
from the materials was observed over 72-hour periods. The 
release profile of SWNT-HBA-DOX and SWNT-DOX was 
similar except to the rate and efficiency. SWNT-HBA-DOX 
and SWNT-DOX conjugates released out of the conjugated 
DOX about 51% and 37% after 12 hours, respectively. 
However, the released portion of SWNT-DOX did not 
exceed 50% of the total amount of loaded drug during the 
experimental period, indicating relatively high stability of 
the π–π   stacking   interaction in the buffer solution. SWNT-
HBA-DOX   liberated 73%, which was higher than that 
of SWNT-DOX of 50% after 60 hours incubation at the 
same conditions. This result showed that the DOX release 
  efficiency from the SWNT-HBA-DOX conjugates was 
higher than that from SWNT-DOX conjugate. There is a 
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Figure 3 (A) Ultraviolet-visible absorbance spectra of PEGylated SWNTs (dotted 
line), free DOX (dash-dotted line), SWNT-DOX (dash line), and SWNT-HBA-DOX 
(solid line) in H2O. (B) Drug weight loading of the DOX-conjugated SWNTs.
Notes: All values are mean ± standard deviation; *denotes P , 0.05.
Abbreviations: DOX, doxorubicin; HBA, hydrazinobenzoic acid; PEG, polyethylene 
glycol; SWNT, single-walled carbon nanotube.
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strong possibility that hydrazone bond may be more sensitive 
than π–π stacking interaction to the lysosome or endosome 
membrane at pH 4.0–5.0.
Intracellular DOX from SWNT-DOX  
and SWNT-HBA-DOX conjugates
The intracellular trafficking of DOX was studied in 
HepG2 cells using confocal microscopy. Figure 5 shows 
the intracellular DOX profile with its intrinsic fluorescence 
after incubating HepG2 cells with SWNT-HBA-DOX and 
SWNT-DOX for 2 hours. The red fluorescence was observed 
in all treated cells, indicating fast cellular internalization 
of DOX. Moreover, when incubating HepG2 cells with 
equivalent concentration of DOX from both formulations 
and for the same period of time, stronger DOX fluorescence 
intensity was detected in both cytoplasm and nuclei from 
SWNT-HBA-DOX-treated cells than that of SWNT-DOX 
conjugate. The fluorescent intensity of DOX at each group 
of treated cells was further quantitatively analyzed. The 
average intracellular fluorescent intensity from SWNT-HBA-
DOX-treated cells was significantly greater than that of 
SWNT-DOX conjugate (Figure 5C). It is difficult to discern 
the difference in cellular uptake of SWNT-HBA-DOX and 
SWNT-DOX nanoconjugates. However, DOX released from 
SWNT-HBA-DOX was significantly improved because the 
intracellular DOX was stronger than that from SWNT-DOX 
conjugate. It was indicated that more DOX was uptaken 
by cells with the help of SWNTs modified with hydrazone 
bond. This result implied that a delivery system comprising 
hydrazone linkage between DOX molecules and SWNTs 
results in more efficient DOX release from lysosomes28,36 
which then moves to the nucleus.
Cytotoxicity of DOX-loaded SWNT 
conjugates
The cytotoxicities of SWNT-HBA-DOX and SWNT-DOX 
with different DOX concentrations against HepG2 after 
24 hours were evaluated using the MTT assay. As shown 
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buffered saline at room temperature at (A) pH 7.4 and (B) pH 5.5.
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Figure 5 Confocal microscope images of HepG2 cells after incubation with (A) SWNT-DOX and (B) SWNT-HBA-DOX (DOX concentration: 15 µg/mL) at 37°C for 
2 hours. (C) Average intracellular DOX fluorescence intensity (20 cells) in SWNT-DOX- and SWNT-HBA-DOX-treated HepG2 cells. 
Notes: Scale bar: 25 µm. All values are mean ± standard deviation; *denotes P , 0.05, analysis of variance.
Abbreviations: DOX, doxorubicin; HBA, hydrazinobenzoic acid; SWNT, single-walled carbon nanotube.
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in Figure 6A, SWNT-HBA-DOX exhibited stronger 
  cytotoxicity than that of SWNT-DOX conjugate at all tested 
concentrations to HepG2 cells. Furthermore, when DOX 
concentration was higher than 5 µg/mL, SWNT-HBA-DOX 
induced significantly enhanced cytotoxicity to HepG2 cells 
than that of SWNT-DOX. The half-maximal inhibitory 
  concentration values for SWNT-HBA-DOX and SWNT-
DOX in HepG2 cells were about 2.8 µg/mL (4.8 µM) and 
4.3 µg/mL (7.4 µM), respectively. This finding is consistent 
with the confocal observation that greater intracellular DOX 
was observed in SWNT-HBA-DOX-treated cells than those 
treated with SWNT-DOX conjugate. Of note, SWNTs them-
selves at the concentrations used for SWNT-HBA-DOX 
and SWNT-DOX formulations did not affect the survival 
of HepG2 cells after exposure to PEGylated SWNTs for up 
to 72 hours (data not shown), which is similar to previous 
reports.9,29 The cytotoxicity of two-drug formulations against 
HeLa cells was also evaluated using MTT assay (Supplemen-
tary Figure 2). The SWNT-HBA-DOX also showed higher 
cytotoxicity to HeLa cells than that of SWNT-DOX conjugate 
under the same experimental conditions.
To further evaluate the drug-release efficiency from 
the SWNTs, HepG2 cells were firstly incubated with 
the SWNT-HBA-DOX and SWNT-DOX complexes 
(DOX   concentration: 10 µg/mL, 17.2 µM) for 2 hours, 
as hyperthermic chemotherapy is often delivered for 
1–2 hours. After the treatment, the treated cell samples 
were further incubated for 24, 48, and 72 hours with fresh 
culture medium, respectively. The cytotoxicity profiles for 
all these agents are illustrated in Figure 6B. After incuba-
tion with fresh medium without drug for 24 hours, the cell 
viability of HepG2 cells exposed to SWNT-HBA-DOX for 
2 hours was significantly lower than that of SWNT-DOX 
conjugate (DOX concentration: 10 µg/mL, 17.2 µM). The 
cell viability decreased with the increase of the incubation 
time (24–72 hours) for both conjugates. The cell viability 
of HepG2 cells exposed to SWNT-HBA-DOX was always 
lower than that of SWNT-DOX conjugate within all tested 
time ranges, which may imply improved drug release 
by SWNT-HBA-DOX conjugate (DOX concentration: 
10 µg/mL, 17.2 µM). Confocal microscope images of the 
treated HepG2 cells (Supplementary Figure 3) also showed 
that the DOX was still retained inside the cells after release 
for 24 hours in fresh medium. The DOX fluorescence 
intensity, as shown in Figure 6C, decreased after release 
for both SWNT-HBA-DOX and SWNT-DOX conjugates. 
However, stronger DOX fluorescence was still observed in 
HepG2 cells treated with SWNT-HBA-DOX than that of 
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Figure  6  Cytotoxicity  of  the  DOX-conjugated  SWNTs.  (A)  Cytotoxicity  of 
SWNT-DOX and SWNT-HBA-DOX against HepG2 cells. (B) Viability of HepG2 cells 
treated with SWNT-DOX and SWNT-HBA-DOX (DOX concentration: 10 µg/mL) 
for 2 hours, washed with phosphate buffered saline, then continued incubating in 
fresh culture media for another 24, 48, and 72 hours. (C) Average intracellular 
DOX fluorescence intensity (20 cells) after release for 24 hours in fresh medium in 
SWNT-DOX- and SWNT-HBA-DOX-treated HepG2 cells.
Notes: All values are mean ± standard deviation; *denotes P , 0.05, analysis of 
variance.
Abbreviations: DOX, doxorubicin; HBA, hydrazinobenzoic acid; SWNT, single-
walled carbon nanotube.
SWNT-DOX conjugate, suggesting the prolonged release 
of DOX from SWNT-HBA-DOX conjugate. The enhanced 
cytotoxicity of SWNT-HBA-DOX is probably due to the 
enhanced cellular uptake of DOX as well as the persistent 
intracellular releases of DOX from SWNT-HBA-DOX 
conjugate.
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Conclusion
A highly effective drug-delivery system based on SWNTs 
coated with DOX through hydrazone bond was developed, 
which improved the loading and release efficiency of DOX. 
The prepared SWNT-HBA-DOX conjugate exhibited a dra-
matic pH responsive drug-release behavior and was stable at 
physiological conditions. The cellular uptake of DOX can 
be enhanced by employing a hydrazone linkage between 
DOX molecules and SWNTs. Consequently, with enhanced 
intracellular accumulation of the drugs, SWNT-HBA-DOX 
conjugate demonstrated significantly improved cytotoxicity 
as compared with SWNT-DOX formed through supramo-
lecular interaction. These results suggest that the hydrazone 
bond appears to be beneficial in developing more efficient 
drug release from SWNT.
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Figure S2 Cytotoxicity of SWNT-DOX and SWNT-HBA-DOX against HeLa cells 
after incubation for 24 h.
Abbreviations: SWNT, single-walled carbon nanotube; DOX, doxorubicin; HBA, 
hydrazinobenzoic acid.
Figure S3 Confocal microscopy image of HepG2 cells treated with (A) SWNT-
DOX and (B) SWNT-HBA-DOX for 2 h, followed by further incubation for 24 h 
in fresh medium. 
Note: Scale bar: 25 µm.
Abbreviations: SWNT, single-walled carbon nanotube; DOX, doxorubicin; HBA, 
hydrazinobenzoic acid.
Supplementary material
Preparation of SWNT-DOX 
In brief, DOX was attached onto SWNT-PEG-NH2 by simply 
mixing 3.6 mg DOX with the PEGylated SWNTs at a nano-
tube concentration of 0.05 mg/mL at pH 7.4 PBS buffered 
solution for 24 hours at room temperature. Unbound DOX 
was removed by dialysis against H2O in a 12–14 K MWCO 
membrane for 3 days. The formed complex (denoted SWNT-
DOX) was stored at 4°C.
Cytotoxicity of HeLa cells by MTT 
methods
HeLa cells were also tested with SWNT-HBA-DOX and 
SWNT-DOX complex. A similar result was observed as 
for HepG2 cells. The cell viability of the HeLa cells after 
incubating in the medium containing SWNT-HBA-DOX 
(2–10 µg/mL) was in the range of 10%–40%, which was 
lower than that of the HeLa cells after incubation with 10 µg/
mL SWNT-DOX (~40%).
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Figure S1 Schematic illustration of the SWNT-DOX. The DOX can be attached to 
SWNT through supramolecular bond.
Abbreviations: SWNT, single-walled carbon nanotube; DOX, doxorubicin.
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